Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys

Wendy W. Yeh, Laura M. Brassard, Caroline A. Miller, Aravind Basavapathruni, Jinrong Zhang, Srinivas S. Rao, Gary J. Nabel, John R. Mascola, Norman L. Letvin, Michael S. Seaman

Research output: Contribution to journalArticle

Abstract

A major goal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent protective antibodies. The initial viral targets of neutralizing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are not known. The identification of early NAb epitopes that induce protective immunity or retard the progression of disease is important for AIDS vaccine development. The aim of this study was to determine the Env residues targeted by early SIV NAbs and to assess the influence of prior vaccination on neutralizing antibody kinetics and specificity during early infection. We previously described stereotypic env sequence variations in SIVmac251-infected rhesus monkeys that resulted in viral escape from NAbs. Here, we defined the early viral targets of neutralization and determined whether the ability of serum antibody from infected monkeys to neutralize SIV was altered in the setting of prior vaccination. To localize the viral determinants recognized by early NAbs, a panel of mutant pseudoviruses was assessed in a TZM-bl reporter gene neutralization assay to define the precise changes that eliminate recognition by SIV Env-specific NAbs in 16 rhesus monkeys. Changing R420 to G or R424 to Q in V4 of Env resulted in the loss of recognition by NAbs in vaccinated monkeys. In contrast, mutations in the V1 region of Env did not alter the NAb profile. These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection.

Original languageEnglish (US)
Pages (from-to)7052-7059
Number of pages8
JournalJournal of Virology
Volume86
Issue number13
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Virus Diseases
Macaca mulatta
Neutralizing Antibodies
neutralizing antibodies
infection
Vaccination
vaccination
AIDS Vaccines
vaccine development
Pseudoviridae
Haplorhini
monkeys
kinetics
antibodies
Antibody Specificity
Antibodies
Human immunodeficiency virus
HIV infections

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Yeh, W. W., Brassard, L. M., Miller, C. A., Basavapathruni, A., Zhang, J., Rao, S. S., ... Seaman, M. S. (2012). Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. Journal of Virology, 86(13), 7052-7059. https://doi.org/10.1128/JVI.00107-12

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. / Yeh, Wendy W.; Brassard, Laura M.; Miller, Caroline A.; Basavapathruni, Aravind; Zhang, Jinrong; Rao, Srinivas S.; Nabel, Gary J.; Mascola, John R.; Letvin, Norman L.; Seaman, Michael S.

In: Journal of Virology, Vol. 86, No. 13, 07.2012, p. 7052-7059.

Research output: Contribution to journalArticle

Yeh, WW, Brassard, LM, Miller, CA, Basavapathruni, A, Zhang, J, Rao, SS, Nabel, GJ, Mascola, JR, Letvin, NL & Seaman, MS 2012, 'Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys', Journal of Virology, vol. 86, no. 13, pp. 7052-7059. https://doi.org/10.1128/JVI.00107-12
Yeh, Wendy W. ; Brassard, Laura M. ; Miller, Caroline A. ; Basavapathruni, Aravind ; Zhang, Jinrong ; Rao, Srinivas S. ; Nabel, Gary J. ; Mascola, John R. ; Letvin, Norman L. ; Seaman, Michael S. / Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. In: Journal of Virology. 2012 ; Vol. 86, No. 13. pp. 7052-7059.
@article{e236bf0dbc494e04bcb53621d3f9d6b8,
title = "Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys",
abstract = "A major goal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent protective antibodies. The initial viral targets of neutralizing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are not known. The identification of early NAb epitopes that induce protective immunity or retard the progression of disease is important for AIDS vaccine development. The aim of this study was to determine the Env residues targeted by early SIV NAbs and to assess the influence of prior vaccination on neutralizing antibody kinetics and specificity during early infection. We previously described stereotypic env sequence variations in SIVmac251-infected rhesus monkeys that resulted in viral escape from NAbs. Here, we defined the early viral targets of neutralization and determined whether the ability of serum antibody from infected monkeys to neutralize SIV was altered in the setting of prior vaccination. To localize the viral determinants recognized by early NAbs, a panel of mutant pseudoviruses was assessed in a TZM-bl reporter gene neutralization assay to define the precise changes that eliminate recognition by SIV Env-specific NAbs in 16 rhesus monkeys. Changing R420 to G or R424 to Q in V4 of Env resulted in the loss of recognition by NAbs in vaccinated monkeys. In contrast, mutations in the V1 region of Env did not alter the NAb profile. These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection.",
author = "Yeh, {Wendy W.} and Brassard, {Laura M.} and Miller, {Caroline A.} and Aravind Basavapathruni and Jinrong Zhang and Rao, {Srinivas S.} and Nabel, {Gary J.} and Mascola, {John R.} and Letvin, {Norman L.} and Seaman, {Michael S.}",
year = "2012",
month = "7",
doi = "10.1128/JVI.00107-12",
language = "English (US)",
volume = "86",
pages = "7052--7059",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "13",

}

TY - JOUR

T1 - Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys

AU - Yeh, Wendy W.

AU - Brassard, Laura M.

AU - Miller, Caroline A.

AU - Basavapathruni, Aravind

AU - Zhang, Jinrong

AU - Rao, Srinivas S.

AU - Nabel, Gary J.

AU - Mascola, John R.

AU - Letvin, Norman L.

AU - Seaman, Michael S.

PY - 2012/7

Y1 - 2012/7

N2 - A major goal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent protective antibodies. The initial viral targets of neutralizing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are not known. The identification of early NAb epitopes that induce protective immunity or retard the progression of disease is important for AIDS vaccine development. The aim of this study was to determine the Env residues targeted by early SIV NAbs and to assess the influence of prior vaccination on neutralizing antibody kinetics and specificity during early infection. We previously described stereotypic env sequence variations in SIVmac251-infected rhesus monkeys that resulted in viral escape from NAbs. Here, we defined the early viral targets of neutralization and determined whether the ability of serum antibody from infected monkeys to neutralize SIV was altered in the setting of prior vaccination. To localize the viral determinants recognized by early NAbs, a panel of mutant pseudoviruses was assessed in a TZM-bl reporter gene neutralization assay to define the precise changes that eliminate recognition by SIV Env-specific NAbs in 16 rhesus monkeys. Changing R420 to G or R424 to Q in V4 of Env resulted in the loss of recognition by NAbs in vaccinated monkeys. In contrast, mutations in the V1 region of Env did not alter the NAb profile. These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection.

AB - A major goal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent protective antibodies. The initial viral targets of neutralizing antibodies (NAbs) early after human or simian immunodeficiency virus (HIV/SIV) infection are not known. The identification of early NAb epitopes that induce protective immunity or retard the progression of disease is important for AIDS vaccine development. The aim of this study was to determine the Env residues targeted by early SIV NAbs and to assess the influence of prior vaccination on neutralizing antibody kinetics and specificity during early infection. We previously described stereotypic env sequence variations in SIVmac251-infected rhesus monkeys that resulted in viral escape from NAbs. Here, we defined the early viral targets of neutralization and determined whether the ability of serum antibody from infected monkeys to neutralize SIV was altered in the setting of prior vaccination. To localize the viral determinants recognized by early NAbs, a panel of mutant pseudoviruses was assessed in a TZM-bl reporter gene neutralization assay to define the precise changes that eliminate recognition by SIV Env-specific NAbs in 16 rhesus monkeys. Changing R420 to G or R424 to Q in V4 of Env resulted in the loss of recognition by NAbs in vaccinated monkeys. In contrast, mutations in the V1 region of Env did not alter the NAb profile. These findings indicate that early NAbs are directed toward SIVmac251 Env V4 but not the V1 region, and that this env vaccination regimen did not alter the kinetics or the breadth of NAbs during early infection.

UR - http://www.scopus.com/inward/record.url?scp=84864133994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864133994&partnerID=8YFLogxK

U2 - 10.1128/JVI.00107-12

DO - 10.1128/JVI.00107-12

M3 - Article

C2 - 22532675

AN - SCOPUS:84864133994

VL - 86

SP - 7052

EP - 7059

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 13

ER -